Pulmonary embolism · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in any Pulmonary embolism compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Any PE · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in any PE compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Postoperative drain volume · People with cancer with perioperative thromboprophylaxis
1 finding from 1 review
Symptomatic DVT · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in symptomatic DVT compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT measured as asymptomatic DVT · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in symptomatic DVT measured as asymptomatic DVT compared with UFH prophylaxis (low certainty).
1 finding from 1 review
Major bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in major bleeding compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in minor bleeding compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Wound hematoma · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis probably leads to lower wound hematoma compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Adverse events (Re‐operation for bleeding (reoperation for major bleeding within 30 days (yes/no))) · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in reoperation for bleeding compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Intraoperative transfusion · People with cancer with perioperative thromboprophylaxis
1 finding from 1 review
Aerobic exercise tolerance (all cancers: 8 to 12 weeks of
3 findings from 1 review
no estimate extracted
10 studies · 604 participants
Low
no estimate extracted
4 studies · 201 participants
Low
no estimate extracted
4 studies · 357 participants
Very low
Aerobic exercise tolerance (all cancers: 6 months)
1 finding from 1 review
Aerobic exercise tolerance (breast cancer: 8‐12 weeks of
1 finding from 1 review
Aerobic exercise tolerance (all cancers: home‐based exercise: 8 to 12 weeks of
1 finding from 1 review
Aerobic exercise tolerance (all cancers:supervised exercise: 8 to 12 weeks of
1 finding from 1 review
The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with no treatment (low certainty).
1 finding from 1 review
Nausea and vomiting · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion showed no clear difference in patient‐reported symptom: nausea/vomiting (EORTC QLQ‐C30) compared with sham treatment (low certainty).
1 finding from 1 review
Diarrhoea · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion showed no clear difference in patient‐reported symptom: diarrhoea (EORTC QLQ‐C30) compared with sham treatment (low certainty).
1 finding from 1 review
Objective outcome measure: WBC count (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion may leads to higher objective outcome measure: WBC count (× 109/L) compared with sham treatment (low certainty).
1 finding from 1 review
Haemoglobin (g/dL) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion may leads to higher objective outcome measure: haemoglobin (g/L) compared with sham treatment (low certainty).
1 finding from 1 review